Clinical Guidelines & Position Statements
|
Publication Date
|
UPDATED: CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs.
- Click here to view the latest version of the guideline on MAGICapp
- Published versions of the guideline in Journal of Rheumatology:
- Click here to view patient decision aid: Your Rheumatoid Arthritis (RA) is Well Controlled with a Biologic or Targeted Medicine: Should you Take Less Medicine?
|
August 2023 |
| NEW: Position Statements on Priority Areas to Support the Sustainability of the Canadian Rheumatology Workforce |
December 2022 |
| UPDATED: CRA Position Statement on Canadian Access to Citrate-free Adalimumab |
November 2022 |
| UPDATED: CRA Position Statement on Biosimilars |
November 2022 |
The CRA living guidelines for the Screening, Monitoring and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
- Click here to view on MAGICapp
- Click here to view published manuscript in the Journal of Rheumatology
|
October 2022 |
| Bridging the Gaps: Optimizing the Transition from Pediatric to Adult Rheumatology Care |
July 2022 |
| Updated CRA Position Statement on COVID-19 Vaccination (PDF) |
March 2022 |
| CRA Recommendation on Three Doses of mRNA Vaccine for Preventing COVID-19 |
November 2021 |
Updated CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease (PDF)
– Submit public comment here
– Decision Tool available here |
November 2021 |
CRA Consensus Statement on the Best Practices for Virtual Care in Rheumatology
– Includes PowerPoint slide infographic |
September 2021 |
| CRA Position Statement on Virtual Care (PDF) |
April 2021 |
| CRA Position Statement on Safety of Hydroxychloroquine in the Treatment of Rheumatic Diseases (PDF) |
January 2021 |
CRA Position Statement on COVID-19 and Hydroxychloroquine Supply (PDF)
– Frequently Asked Questions |
April 2020 |
| Canadian Rheumatology Association Policy on Potential Conflicts of Interest in the Guideline Development Process (PDF) |
June 2019 |
| Canadian Rheumatology Association Guidelines Handbook (PDF) |
May 2019 |
Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease
– Frequently Asked Questions |
January 2019 |
| Canadian Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus |
August 2018 |
| Canadian Position Statement on Opioid Therapy (PDF) |
November 2017 |
| Canadian Position Statement on Management of Juvenile Idiopathic Arthritis |
October 2016 |
| Canadian Position Statement on Ethical Prescribing (PDF) |
November 2015 |
| Editorial: Expanding Medical Marijuana Access in Canada (PDF) |
November 2015 |
| Canadian Review on Cannabinoid Treatments for Rheumatic Diseases |
November 2015 |
| Canadian Recommendations for the Management of Spondyloarthropathy |
April 2014 |
Cardiovascular Risk with Diclofenac: Response to Health Canada (PDF)
Reviewed by Therapeutics Committee in November 2021 and no changes made. |
November 2014 |
| Chronic pain, Diclofenac and Cardiovascular Risk: Management Algorithm (PDF) |
June 2014 |
| Canadian Confidence with Cannabinoids in Rheumatic Diseases: A Survey of Rheumatologists (PDF) |
November 2014 |
| Canadian Recommendations for Management of RA |
August 2012 |
| Canadian Fibromyalgia Guidelines |
August 2012 |
